Authors
Latest:
Urology Practice advice: Real estate pitfalls to avoidCommercial real estate can be one of the highest expenses for health care practices.
Latest:
Exciting Prospects for the Future of Localized Prostate Cancer TreatmentDr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.
Latest:
Unmet Needs for the Treatment of Enteric HyperoxaluriaDr. Kyle Wood discusses optimal avenues to increase patient and provider education on enteric hyperoxaluria and provides closing thoughts on the future management of enteric hyperoxaluria.
Latest:
What a long-term study of patients undergoing RARC reveals about upstaging“High risk, non–muscle invasive bladder cancer carries a significant risk of recurrence and progression. This emphasizes the need for careful patient selection, especially when we are considering bladder-sparing approaches," says Neeraja Tillu, MD.
Latest:
A Look Into The Future of PSMA-Targeted Therapies in Prostate CancerPanelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Adam Lorentz, MD, on predictions for future advances in robotics“Then recently, of course, with the single-port device, that has truly allowed us to be less invasive with our robotic approaches,” says Adam Lorentz, MD, FACS.
Latest:
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUCVitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Future of Overactive Bladder TreatmentDrs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.
Latest:
Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR AlterationPanelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.
Latest:
Urologist discusses when to say “no” as a professional"Saying 'no' is one of our biggest challenges in our careers as physicians," according to Phillip M. Pierorazio, MD.
Latest:
A primer on DNA sequencing for the practicing urologistEmbracing and understanding new and emerging molecular techniques will improve patient outcomes.
Latest:
Ernest Morton, MD, shares initial findings on the use of an AI scribe“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA, MS.
Latest:
Reining in the administrative burden in health careDoctors and medical practices are mired in administrative tasks.
Latest:
Congress to again consider prior authorization reform legislationThe bill has a mass of legislative supporters – at least 41 senators and 127 representatives, along with more than 370 organizations representing patients, physicians, hospitals and Medicare Advantage plans.
Latest:
Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCCThe phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma.
Latest:
3D bioprinting technology facilitates development of an in vitro biomimetic bladder model"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
Latest:
Final Thoughts and Clinical Trials in NMIBCExperts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).
Latest:
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.
Latest:
iRARC adoption is slow but persistent in bladder cancer"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Latest:
Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinomaAdjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Talazoparib/enzalutamide significantly boosts OS in mCRPC"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Latest:
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health“What [we] found was that those men who received a penile implant had a significant reduction in depression and psychological distress," says Mohit Khera, MD, MBA, MPH.
Latest:
Reimplantation of Tibial Nerve Stimulation Device (eCoin)OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).
Latest:
18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.
Latest:
Future Directions in mCRPCPanelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Latest:
Physician highlights AI’s potential to improve practice efficiency and alleviate burnoutArtificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.
